Prognostic Significance of the Modified Glasgow Prognostic Score in Patients Undergoing FOLFOXIRI plus Bevacizumab Therapy for Advanced or Metastatic Colorectal Cancer
Pretreatment mGPS is a simple and useful prognostic factor for mCRC patients receiving FOLFOXIRI + BV therapy and may serve as a convenient indicator for accurate prognosis prediction and treatment decision-making.
Authors
- Yukari Ono
- Mamoru Uchiyama
- Kenta Iguchi (ORCID: https://orcid.org/0000-0003-3049-0904)
- Masahiro Asari
- Manabu Shiozawa (ORCID: https://orcid.org/0009-0006-1912-5948)
- Keisuke Kazama (ORCID: https://orcid.org/0000-0002-8155-8561)
- Koji Numata (ORCID: https://orcid.org/0000-0002-8434-3320)
- Norio Yukawa
- Aya Saito
Institutions
- Kanagawa Prefectural Hospital Organization (JP)
- Kanagawa Cancer Center
- Yokohama City University (JP)
Publication Details
- Journal
- Oncology
- Published
- 2025-05-26
- DOI
- https://doi.org/10.1159/000546260
- Primary Topic
- Inflammatory Biomarkers in Disease Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00